Sign in
Taking people in SwedenPhase 1

A skin emulsion called TIR-C for adults with atopic dermatitis

Tests TIR-C skin emulsion in adults with atopic dermatitis.

Key facts

Who runs it
Pharmability AB
Where
Linkoping, Moelndal, Solna, and Uppsala, SwedenSee the 4 sites
Registry title
A double-blind, randomised, placebo-controlled first-in-human/Phase Ib trial to investigate safety, tolerability, pharmacokinetics, and preliminary efficacy of single and multiple doses of TIR-C 2% cutaneous emulsion in adults with mild to moderate atopic dermatitis
Status
Recruiting
Phase
Phase 1
People taking part
52 people, planned
Started
14 Sept 2026
Expected to end
30 Jun 2027
Type of study
Interventional
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with mild to moderate atopic dermatitis (a long-lasting itchy skin condition). It tests TIR-C 2% cutaneous emulsion against a placebo.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Mild to moderate atopic dermatitis

Main reasons for not taking part

  • Healthy volunteers cannot join.

Where in Sweden

  • CTC Clinical Trial Consultants ABLinkoping, SwedenTaking people
  • CTC Clinical Trial Consultants ABMoelndal, SwedenTaking people
  • CTC Clinical Trial Consultants ABSolna, SwedenTaking people
  • CTC Clinical Trial Consultants ABUppsala, SwedenTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
A skin emulsion called TIR-C for adults with atopic dermatitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
5 November 2026